Cargando…

Silent atrial fibrillation in patients with an implantable cardioverter defibrillator and coronary artery disease (INDICO AF) trial: study rationale and design

BACKGROUND: Timely detection of atrial fibrillation (AF) in implantable cardioverter defibrillator (ICD) patients is clinically important for prevention of AF-related complications and inappropriate shocks. Patients with coronary artery disease (CAD) and a dual or triple chamber ICD show a high inci...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baalman, S. W. E., Boersma, L. V. A., Allaart, C. P., Meine, M., Scheerder, C. O. S., de Groot, J. R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bohn Stafleu van Loghum 2018
Materias:	Original Article – Design Study Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288037/ https://www.ncbi.nlm.nih.gov/pubmed/30357612 http://dx.doi.org/10.1007/s12471-018-1185-2

Ejemplares similares

Design and rationale of the MODULAR ATP global clinical trial: A novel intercommunicative leadless pacing system and the subcutaneous implantable cardioverter-defibrillator
por: Lloyd, Michael S., et al.
Publicado: (2023)

Do we understand the rationale behind driving restrictions in patients with an implantable cardioverter defibrillator?
por: Baalman, S. W. E., et al.
Publicado: (2018)

Electrographic flow–guided ablation in redo patients with persistent atrial fibrillation (FLOW-AF): design and rationale
por: Szili-Torok, Tamas, et al.
Publicado: (2023)

The extravascular implantable cardioverter‐defibrillator: The pivotal study plan
por: Crozier, Ian, et al.
Publicado: (2021)

Atrial fibrillation fingerprinting; spotting bio‐electrical markers to early recognize atrial fibrillation by the use of a bottom‐up approach (AFFIP): Rationale and design
por: Starreveld, Roeliene, et al.
Publicado: (2020)

Induced atrial fibrillation during defibrillation test on implantation of subcutaneous implantable cardioverter defibrillator
por: Kim, Ki-Hun, et al.
Publicado: (2020)

PREVENTION-ACHD: PRospEctiVE study on implaNTable cardioverter-defibrillator therapy and suddeN cardiac death in Adults with Congenital Heart Disease; Rationale and Design
por: Vehmeijer, J. T., et al.
Publicado: (2019)

The PhysioVP-AF study, a randomized controlled trial to assess the clinical benefit of physiological ventricular pacing vs. managed ventricular pacing for persistent atrial fibrillation prevention in patients with prolonged atrioventricular conduction: design and rationale
por: Pastore, Gianni, et al.
Publicado: (2023)

Atrial CARdiac Magnetic resonance imaging in patients with embolic stroke of unknown source without documented Atrial Fibrillation (CARM-AF): Study design and clinical protocol
por: Kotadia, Irum D., et al.
Publicado: (2022)

Low efficacy of cardioversion of persistent atrial fibrillation with the implantable cardioverter-defibrillator
por: Limantoro, I., et al.
Publicado: (2013)

Internal cardioversion of persistent atrial fibrillation in implantable cardioverter defibrillator patients: the juice is not worth the squeeze
por: Berger, W. R., et al.
Publicado: (2013)

Rationale and design of the impact of anticoagulation therapy on the Cognitive Decline and Dementia in Patients with Nonvalvular Atrial Fibrillation (CAF) Trial: A Vanguard study
por: Bunch, T. Jared, et al.
Publicado: (2019)

Cardiac Magnetic Resonance Imaging–Derived Left Atrial Characteristics in Relation to Atrial Fibrillation Detection in Patients With an Implantable Cardioverter‐Defibrillator
por: Hopman, Luuk H. G. A., et al.
Publicado: (2023)

Improving outcomes of AF ablation by integrated personalized lifestyle interventions: rationale and design of the prevention to improve outcomes of PVI (POP) trial
por: Vermeer, Jasper, et al.
Publicado: (2023)

Dual‐chamber implantable cardioverter–defibrillator. Is it useful in patient with permanent atrial fibrillation?
por: Porres‐Aracama, José M., et al.
Publicado: (2016)

Rationale and design of a randomized trial of the dapagliflozin evaluation on atrial fibrillation patients followed Cox-Maze IV: the DETAIL-CMIV study
por: Peng, Zhan, et al.
Publicado: (2023)

The Gulf Implantable Cardioverter-defibrillator Registry: Rationale, Methodology, and Implementation
por: Alsheikh-Ali, Alawi A., et al.
Publicado: (2015)

A randomized controlled trial of pulsed field ablation versus standard-of-care ablation for paroxysmal atrial fibrillation: The ADVENT trial rationale and design
por: Reddy, Vivek Y., et al.
Publicado: (2023)

Long‐term follow‐up of the two‐incision implantation technique for the subcutaneous implantable cardioverter‐defibrillator
por: van der Stuijt, Willeke, et al.
Publicado: (2020)

Patient perspective on remote monitoring of cardiovascular implantable electronic devices: rationale and design of the REMOTE-CIED study
por: Versteeg, H., et al.
Publicado: (2014)

EvaluatioN of ApiXaban in strOke and systemic embolism prevention in patients with non‐valvular atrial fibrillation in clinical practice Setting in France, rationale and design of the NAXOS: SNIIRAM study
por: Picard, Fabien, et al.
Publicado: (2019)

Evolving use and indications for implantable cardioverter defibrillators
por: de Groot, J. R.
Publicado: (2018)

Diagnosis of atrial fibrillation in heart failure patients with implantable cardioverter defibrillator or cardiac resynchronisation therapy
por: Dominik, Barbara, et al.
Publicado: (2021)

Implantable Cardioverter-Defibrillator Implantation in a Patient with Atrial Standstill
por: Park, So Ra, et al.
Publicado: (2009)

Design and Rationale of the PRAGUE‐12 Trial: A Large, Prospective, Randomized, Multicenter Trial That Compares Cardiac Surgery With Left Atrial Surgical Ablation With Cardiac Surgery Without Ablation in Patients With Coronary and/or Valvular Heart Disease Plus Atrial Fibrillation
por: Straka, Zbyněk, et al.
Publicado: (2012)

Implantable cardioverter-defibrillators /
Publicado: (1994)

Evolution of extravascular implantable cardioverter-defibrillator therapy for ventricular arrhythmias
por: Römers, Hans, et al.
Publicado: (2022)

Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C
por: Reddy, K Rajender, et al.
Publicado: (2012)

A randomized sham‐controlled study of pulmonary vein isolation in symptomatic atrial fibrillation (The SHAM‐PVI study): Study design and rationale
por: Dulai, Rajdip, et al.
Publicado: (2023)

Atrial pacing–induced oversensing in subcutaneous implantable cardioverter-defibrillator
por: Wharmby, Amy, et al.
Publicado: (2023)

The efficacy and safety of left atrial low‐voltage area guided ablation for recurrence prevention compared to pulmonary vein isolation alone in patients with persistent atrial fibrillation trial: Design and rationale
por: Sunaga, Akihiro, et al.
Publicado: (2021)

Use of wearable cardioverter‐defibrillator in association with catheter ablation for atrial fibrillation‐related tachycardiomyopathy
por: Conti, Sergio, et al.
Publicado: (2019)

Dutch outcome in implantable cardioverter-defibrillator therapy (DO-IT): registry design and baseline characteristics of a prospective observational cohort study to predict appropriate indication for implantable cardioverter-defibrillator
por: van Barreveld, M., et al.
Publicado: (2017)

Deactivation of implantable cardioverter-defibrillators
por: Wan, Darryl, et al.
Publicado: (2021)

Dutch Outcome in Implantable Cardioverter‐Defibrillator Therapy: Implantable Cardioverter‐Defibrillator–Related Complications in a Contemporary Primary Prevention Cohort
por: van Barreveld, Marit, et al.
Publicado: (2021)

Driving restrictions for Dutch patients with an implantable cardioverter defibrillator: Compliance and associated factors
por: Jongejan, N., et al.
Publicado: (2017)

The subcutaneous implantable cardioverter-defibrillator should be considered for all patients with an implantable cardioverter-defibrillator indication
por: Tan, Jian Liang, et al.
Publicado: (2022)

Optimizing patient selection for primary prevention implantable cardioverter-defibrillator implantation: utilizing multimodal machine learning to assess risk of implantable cardioverter-defibrillator non-benefit
por: Kolk, Maarten Z H, et al.
Publicado: (2023)

Edoxaban Management in Diagnostic and Therapeutic Procedures (EMIT‐AF/VTE)—Trial design
por: Colonna, Paolo, et al.
Publicado: (2018)

Oversensing of atrial fibrillatory waves in a subcutaneous implantable cardioverter-defibrillator
por: Karnik, Ankur A., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_h7deqo7dggqq2hnelku0hc0n18